Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome

American Journal of Ophthalmology

Volumn 156, Issue 1, 2013, Pages

  Czyz, Craig N ^a,b   Burns, John A ^b,c   Petrie, Thomas P ^a   Watkins, John R ^d   Cahill, Kenneth V ^b,c   Foster, Jill A ^a,b,c  

^a OHIO UNIVERSITY   (United States)

^b GRANT MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; ARTICLE; BLEPHAROSPASM; CLINICAL ARTICLE; DIPLOPIA; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRY EYE; DYSTONIA; EYE IRRITATION; EYE PAIN; FEMALE; HEMIFACIAL SPASM; HUMAN; INCIDENCE; MALE; MEIGE DISEASE; MEIGE SYNDROME; PHOTOSENSITIVITY; PRIORITY JOURNAL; PTOSIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84879244009     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.02.001     Document Type: Article

References (26)

1. G. Cossu, A. Mereu, and M. Deriu Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey Mov Disord 21 11 2006 2005 2008
2. C. Kenney, and J. Jankovic Botulinum toxin in the treatment of blepharospasm and hemifacial spasm J Neural Transm 115 4 2008 585 591
3. G.J. Ben Simon, and J.D. McCann Benign essential blepharospasm Int Ophthalmol Clin 45 3 2005 49 75
4. J. Jankovic Blepharospasm with basal ganglia lesions Arch Neurol 43 9 1986 866 868
5. J. Jankovic, and S.C. Patel Blepharospasm associated with brainstem lesions Neurology 33 9 1983 1237 1240
6. K.L. Leenders, R.S.J. Frackowiak, N. Quinn, D. Brooks, D. Sumner, and C.D. Marsden Ipsilateral blepharospasm and contralateral hemidystonia and parkinsonism in a patient: CT, MRI and PET scanning Mov Disord 1 1 1986 51 58
7. S.P. Kraft, and A.E. Lang Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin CMAJ 139 9 1988 837 844
8. F. Grandas, J. Elston, N. Quinn, and C.D. Marsden Blepharospasm: a review of 264 patients J Neurol Neurosurg Psychiatry 51 6 1988 767 772
9. A. Albanese, F. Asmus, and K.P. Bhatia EFNS guidelines on diagnosis and treatment of primary dystonias Eur J Neurol 18 1 2011 5 18
10. C. Colosimo, A. Suppa, G. Fabbrini, M. Bologna, and A. Berardelli Craniocervical dystonia: clinical and pathophysiological features Eur J Neurol 17 Suppl 1 2010 Jul 15 21
11. D.M. Simpson, A. Blitzer, and A. Brashear Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology Neurology 70 19 2008 1699 1706
12. M.Z. Atassi Basic immunological aspects of botulinum toxin therapy Mov Disord 19 Suppl 8 2004 S68 S84
13. M.F. Brin, C.L. Comella, and J. Jankovic Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay Mov Disord 23 10 2008 1353 1360
14. P. Greene, S. Fahn, and B. Diamond Development of resistance to botulinum toxin type A in patients with torticollis Mov Disord 9 2 1994 213 217
15. P. Haussermann, S. Marczoch, C. Klinger, M. Landgrebe, B. Conrad, and A. Ceballos-Baumann Long-term follow-up of cervical dystonia patients treated with botulinum toxin A Mov Disord 19 3 2004 303 308
16. J. Jankovic Clinical features, differential diagnosis and pathogenesis of blepharospasm and cranial-cervical dystonia Adv Ophthalmic Plast Reconstr Surg 4 1985 67 82
17. J. Jankovic, and J. Ford Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients Ann Neurol 13 4 1983 402 411
18. C.D. Marsden Dystonia: the spectrum of the disease Res Publ Assoc Res Nerv Ment Dis 55 1976 351 367
19. R.G. Auger, and J.P. Whisnant Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984 Arch Neurol 47 11 1990 1233 1234
20. S. Jitpimolmard, S. Tiamkao, and M. Laopaiboon Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases J Neurol Neurosurg Psychiatry 64 6 1998 751 757
21. N.I. Mejia, K.D. Vuong, and J. Jankovic Long-term botulinum toxin efficacy, safety, and immunogenicity Mov Disord 20 5 2005 592 597
22. J.R. Ainsworth, and S.P. Kraft Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm Ophthalmology 102 12 1995 2036 2040
23. G. Defazio, G. Abbruzzese, and P. Girlanda Botulinum toxin A treatment for primary hemifacial spasm. A 10-year multicenter study Arch Neurol 59 3 2002 418 420
24. G.Y.R. Hsiung, S.K. Das, R. Ranawaya, A.L. Lafontaine, and O. Suchowersky Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period Mov Disord 17 6 2002 1288 1293
25. Z. Nussgens, and P. Roggenkamper Long-term treatment of blepharospasm with botulinum toxin type A Ger J Ophthalmol 4 6 1995 363 367
26. S.L. Matarasso Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides Dermatol Surg 29 1 2003 7 13